Biotechnology

Summit Therapeutics

Wall Street Zen Upgrades Summit Therapeutics Stock Rating

Summit Therapeutics released FY2026 Q1 earnings on April 30 (EST), actual revenue USD 0 (forecast USD 53.86 K), actual EPS USD -0.2442 (forecast USD -0.2751)

Summit Therapeutics Sees Narrowed Losses in First Quarter Despite Rising R&D Costs

Summit Therapeutics Inc. Advances Ivonescimab Clinical Trials, FDA Accepts BLA

Summit Treatments to Present Ivonescimab Phase III Data at European Lung Cancer Congress

Summit Therapeutics Reports Q4 Earnings, Highlights Positive Clinical Trial Results and Strong Cash Position

Summit Therapeutics released FY2025 Q4 earnings on February 23 After-Market EST: Actual Revenue USD 0 (Forecast USD 76.45 M), Actual EPS USD 0 (Forecast USD -0.1398)

Summit Therapeutics released FY2025 earnings on February 23 After-Market EST, actual revenue USD 0 (forecast USD 76.45 M), actual EPS USD -1.4438 (forecast USD -1.2758)

Summit Therapeutics Reports FY2025 Operating Expenses and Losses

Summit Therapeutics to Release FY2025 Q4 Earnings on February 23 After-Market EST, Forecast Revenue USD 78.28 M, EPS USD -0.1599

Summit Therapeutics Submits BLA to FDA for Ivonescimab

FactSet analysts downgrade Summit Therapeutics 2025 EPS forecast

FactSet: Summit Therapeutics 2025 EPS Forecast Revised Up to -1.42 USD

FactSet Revises Summit Therapeutics Inc's 2025 EPS Forecast to -1.47 USD

TD Cowen Analyst Maintains Buy Rating on Summit Therapeutics

Clear Street Analyst Maintains Buy Rating on Summit Therapeutics

Summit Therapeutics Reports Positive Phase III HARMONi-A Trial Results for Ivonescimab Plus Chemotherapy in EGFR-Mutated Non-Small Cell Lung Cancer

Analyst Goonewardene Continues to Cover and Rate Healthcare Company Summit Therapeutics

Summit Therapeutics Inc's Ivonescimab Succeeds in Phase III Trial for NSCLC

Daisy Gives Summit Therapeutics a Buy Rating

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

Silexion Therapeutics

GCL Global

Arcadia Biosciences

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Bristol-Myers Squibb Company

AGYS

CAVA

SMMT

Today, notable options trading activity was observed in CAVA Group Inc (CAVA) with 26,409 contracts traded, representing 2.6 million shares, primarily in the $115 strike call option. Agilysys Inc (AGYS) saw 2,493 contracts, about 249,300 shares, with significant activity in the $75 strike call option. Summit Therapeutics Inc (SMMT) had 44,452 contracts traded, equating to 4.4 million shares, focusing on the $26 strike call option. These volumes reflect substantial percentages of their respective average daily trading volumes.

nasdaq

Agilysys

Cava

S&P 500

Notable Tuesday Option Activity: CAVA, AGYS, SMMT

ZETA

Analysts recommend three stocks for this week: Zeta Global (ZETA), Boston Scientific (BSX), and Summit Therapeutics (SMMT). Each stock has catalysts such as earnings and product launches, with a 'Strong Buy' consensus and over 40% upside potential in the next year. Investors are encouraged to research these stocks further before making decisions.

Tip Ranks

Zeta Global

Boston Scientific

3 Best Stocks to Buy This Week, According to Analysts – May 18-May 22

SBIO

LABU

IBBQ

Summit Therapeutics Inc. reported a significant widening of its net loss to $189.42 million for Q1 2026, compared to $62.91 million a year earlier. This raises concerns about the company's financial health and funding flexibility as it seeks to advance its late-stage oncology pipeline, particularly the ivonescimab program. The FDA has accepted Summit's BLA for ivonescimab, with a target action date of November 14, 2026. Analysts' revenue forecasts for 2029 vary widely, with some projecting up to $3.1 billion, but the recent loss may lead to revised expectations.

Simplywall

VanEck Biotech ETF

ALPS Medical Breakthrough

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

Summit Therapeutics (SMMT) Is Down 20.1% After Q1 2026 Net Loss Widens Sharply

TD Cowen analyst Tyler Van Buren has reiterated a Buy rating on Summit Therapeutics (SMMT) due to a stable long-term sales outlook and an attractive risk/reward profile. Despite raising future operating expense projections, he maintained sales expectations, reflecting confidence in the company's growth potential. Encouraged by management's commentary and clinical updates, Van Buren believes the stock remains a solid investment. H.C. Wainwright also supports this view with a Buy rating and a $23.00 price target.

Proshares Ultra Nasdaq Biotech

Toronto Dominion Bank

Tyler Van Buren Reiterates Buy on Summit Therapeutics, Citing Stable Long-Term Sales Outlook and Attractive Risk/Reward Despite Higher Future OpEx

JPMorgan's research report indicates that AKESOis likely to meet its final analysis target for lung cancer trials, despite a recent interim analysis by partner Summit Therapeutics Inc.showing no statistical significance, which caused a 25% drop in Summit's share price. JPM maintains an Overweight rating on AKESO with a target price of HKD162, citing a high probability of success for the final analysis expected in 2H26.

AASTOCKS News

VG Health

Ark Genomic Revolution ETF

iShares US Pharma

JPMorgan Chase

AKESO

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

JPM: AKESO  Lung Cancer Trial Final Analysis Likely to Meet Target; Rating Overweight

Summit Therapeutics (SMMT) faces significant scrutiny after its stock plummeted due to the continuation of its Phase III ivonescimab trial without early efficacy signals and a warning of going concern. The stock saw a 1-day drop of -24.91% and a 7-day drop of -27.15%. Despite a 3-year total shareholder return of around 7x, the current P/B ratio of 19x raises concerns about the optimism priced in. Analysts suggest a fair value of $29.18, indicating the stock may be undervalued, but risks remain regarding regulatory hurdles and R&D spending.

A Look At Summit Therapeutics (SMMT) Valuation After Trial Update And Going Concern Warning

Summit Therapeutics Inc. reported a widening net loss of $189.4 million for Q1 2026, with a loss per share of $0.24. The company is advancing Phase III trials for ivonescimab and has received FDA acceptance for its Biologics License Application, with a PDUFA goal date of November 14, 2026. The upcoming overall survival data from the HARMONi-6 trial is critical for the company's future, as rising losses and cash burn pose risks. Analysts project significant revenue growth by 2029, but the reliance on a single drug raises concerns about investment viability.

Summit Therapeutics (SMMT) Is Down 27.0% After HARMONi-6 OS Plenary, BLA Progress And Wider Losses - Has The Bull Case Changed?

Summit Therapeutics (SMMT) received a Hold rating from analyst Faisal Khurshid of Jefferies, with a price target of $17.00, while shares closed at $16.12. Khurshid has a 69.1% average return and 62.77% success rate. The analyst consensus for Summit is Strong Buy, with a price target of $31.42, indicating a 94.97% upside. Piper Sandler also maintained a Hold rating with a $16.00 price target.

Jefferies Financial

Syndax Pharma

Revolution Medicines

Piper Sandler Cos

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

Summit Therapeutics (SMMT) Receives a Rating Update from a Top Analyst

Wall Street Zen upgraded Summit Therapeutics (NASDAQ:SMMT) from a "strong sell" to a "sell" rating. Other analysts have varied opinions, with Stifel Nicolaus giving a "buy" rating and a $45 target, while Jefferies lowered their rating to "hold" with a $15 target. Currently, the stock has a consensus rating of "Moderate Buy" and a price target of $28.17. Summit Therapeutics reported a quarterly EPS of ($0.24), exceeding estimates. The company focuses on precision medicines for serious diseases, with its lead asset targeting Clostridioides difficile infections.

Market Beat

Citigroup

T. Rowe Price

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Summit Therapeutics (NASDAQ:SMMT) Raised to "Sell" at Wall Street Zen

Summit Therapeutics PLC (SMMT) has flagged a significant going-concern risk due to insufficient cash and short-term investments to fund operations for the next twelve months. The company's reliance on uncertain external financing may lead to operational cutbacks or cessation of activities if capital cannot be raised. Despite this, the average stock price target is $31.25, indicating a potential upside of 93.92%.

Summit Therapeutics Flags Significant Going-Concern Risk Amid Cash Shortfall and Uncertain Financing

Summit Therapeutics(SMMT.US)